<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Clarient Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/clarient-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(GHDX) Genomic Health&#8217;s Results Reveal Oncotype DX Utility</title>
		<link>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568</link>
		<comments>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568#comments</comments>
		<pubDate>Wed, 14 Oct 2009 16:28:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Clarient Inc]]></category>
		<category><![CDATA[CLRT]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17568</guid>
		<description><![CDATA[Recently, Genomic Health Inc. (GHDX) announced data which confirmed that manual micro dissection (dissection of tissue or cells under the microscope) of biopsy cavities is essential for the accurate assessment of recurrence risk in patients with early-stage breast cancer. Genomic Health&#8217;s Oncotype DX is the only commercially available breast cancer test that makes use of manual microdissection following review by a board certified surgical pathologist with expertise in breast cancer to predict a patient&#8217;s benefit from chemotherapy and risk of disease recurrence. The results from the study revealed that the inclusion of biopsy cavities in breast cancer specimens is associated with significant changes in the expression of individual genes. Consequently, it was found that biopsy cavities had high-risk Recurrence Scores. Genomic also presented results which demonstrated ability of Oncotype DX ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

